UK pharmaceutical conglomerate AstraZeneca and India-based generics maker Ranbaxy Laboratories failed to have a landmark lawsuit ended early, say reports, and the companies will continue to face charges of an anticompetitive pay-for-delay agreement.
US District Judge William Young ruled Monday that the companies cannot end the jury trial early despite claims by the companies that the plaintiffs did not provide enough evidence of the alleged pay-for-delay scheme.
The charges surround the medication known as Nexium.
Reports say the case is the first of its kind since the US Supreme Court ruled against Actavis in deciding that pay-for-delay deals can be anticompetitive.
Meanwhile, reports say Teva Pharmaceuticals decided to settle the matter; details of the settlement, however, were not made public.
The trial began last October.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Court Order Temporarily Halts U.S. Consumer Financial Protection Bureau Layoffs
Feb 16, 2025 by
CPI
Nokia Poised to Gain EU Approval for $2.3 Billion Infinera Acquisition
Feb 16, 2025 by
CPI
Turkey Fines Frito-Lay in Antitrust Crackdown
Feb 16, 2025 by
CPI
Advances Bill to Strengthen Antitrust Enforcement Through AI
Feb 16, 2025 by
CPI
Intel Faces Potential Breakup as Broadcom and TSMC Explore Deals
Feb 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon